Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details) - USD ($)				1 Months Ended		3 Months Ended		6 Months Ended
	May 11, 2020	Jun. 24, 2018	Oct. 02, 2017	Jun. 30, 2018	Oct. 31, 2017	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
In process research and development				$ 20,000,000		$ 15,000	$ 15,000	$ 35,000	$ 45,000
Pulmokine, Inc. | License Agreement | In Process Research And Development Seralutinib
Business Acquisition [Line Items]
Product license term (in years)			10 years
Upfront payment					$ 5,500,000
Milestones accrued						0		0		$ 5,000,000
Pulmokine, Inc. | License Agreement | In Process Research And Development Seralutinib | Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable			$ 58,000,000
Commercial milestone payments, payable			45,000,000
Sales milestone payments, payable			$ 190,000,000
Aerpio Pharmaceuticals, Inc. | License Agreement | In Process Research And Development G B Zero Zero Four
Business Acquisition [Line Items]
Upfront payment	$ 15,000,000
Milestones accrued						$ 0		$ 0
Participation rights (as a percent)		20.00%
Aerpio Pharmaceuticals, Inc. | License Agreement | In Process Research And Development G B Zero Zero Four | Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable	40,000,000
Sales milestone payments, payable	$ 50,000,000